李艳

[摘要] 目的 分析美托洛爾联合曲美他嗪治疗冠心病心力衰竭的临床效果，并探讨其对患者心功能指标的影响。 方法 将我院2014年11月～2016年11月期间所收治的148例冠心病心力衰竭患者作为本次研究对象，随机分为两组，对照组和实验组各74例，对照组采取常规治疗，实验组在此基础上应用美托洛尔联合曲美他嗪治疗，对比分析两组患者的临床治疗效果，并比较两组患者的心功能改善情况。 结果 两组在心率与收缩压方面差异无统计学意义（P>0.05）；实验组的临床治疗总有效率为95.95%，显著高于对照组（81.08%），且实验组LVEF（51.7±3.7）%、LVESD（34.7±3.5）mm、LVEDD（54.7±4.2）mm明显优于对照组[（45.3±3.1）%、（39.8±2.7）mm、（60.5±4.1）mm]，两组差异具有统计学意义（P<0.05）。 结论 美托洛尔与曲美他嗪联合治疗冠心病心力衰竭的临床效果明显，能够有效提高患者的临床总有效率，并对改善患者心功能存在明显优势，值得推广应用。

[关键词] 美托洛尔；曲美他嗪；冠心病；心力衰竭

[中图分类号] R541.4 [文献标识码] B [文章编号] 1673-9701（2017）25-0042-03

Analysis on the clinical effect of metoprolol combined with trimetazidine in the treatment of coronary heart disease complicated with heart failure

LI Yan

Laiwu Central Hospital， Xinwen Mining Group， Laiwu 271100， China

[Abstract] Objective To analyze the clinical effect of metoprolol combined with trimetazidine in the treatment of coronary heart disease complicated with heart failure， and to explore its effect on patients' cardiac function. Methods 148 patients with coronary heart disease complicated with heart failure who were admitted to our hospital from November 2014 to November 2016 were selected as the study subjects. The patients were randomized to different groups for treatment. There were 74 patients in the control group and the experimental group. The control group was given routine treatment， and the experimental group was given metoprolol combined with trimetazidine for the treatment on the basis of the control group. The effect of clinical treatment was compared and analyzed in the two groups， and the improvement of cardiac function was compared between the two groups. Results There was no statistically significant difference in heart rate and systolic blood pressure between the two groups（P>0.05）； the total effective rate of clinical treatment in the experimental group was 95.95%， significantly higher than the control group（81.08%）. LVEF was（51.7±3.7）%， LVESD was（34.7±3.5）mm and LVEDD was（54.7±4.2）mm in the experimental group were significantly better than those in the control group[（45.3±3.1）%， （39.8±2.7）mm， （60.5±4.1）mm）]. The differences between the two groups were statistically significant（P<0.05）. Conclusion The clinical effect of metoprolol combined with trimetazidine in the treatment of coronary heart disease complicated with heart failure is significant， which can effectively improve the clinical total effective rate of patients， and has a significant advantage in improving the patient's heart function， which is worthy of promotion and application.endprint

[Key words] Metoprolol； Trimetazidine； Coronary heart disease； Heart failure

冠心病属于心血管内科的常见疾病之一，随着该病症的发生，伴随着较多并发症出现，心力衰竭就是其中最为严重的并发症之一[1-2]，能够威胁患者的生命安全。为改善患者的生活质量，临床学者对冠心病心力衰竭的治疗进行研究，发现美托洛尔联合曲美他嗪治疗冠心病心力衰竭的效果较为明显[3-4]，基于此，本文选择我院2014年11月～2016年11月期间所收治的148例冠心病心力衰竭患者进行探讨，现报道如下。

1资料与方法

1.1 一般资料

对2014年11月～2016年11月我院收治的148例冠心病心力衰竭患者进行分析，对患者进行随机分组，分为实验组（n=74）与对照组（n=74）。所有患者均符合WHO冠心病心力衰竭的诊断标准[5]，且148例患者中无严重肝肾功能异常者、无其他原因引起的心力衰竭者。参照……